Small molecule and peptide-based CXCR4 modulators as therapeutic agents. A patent review for the period from 2010 to 2018

References

• Chen K, Bao Z, Tang P, et al. Chemokines in homeostasis and diseases. Cell Mol Immun. 2018;15:324–334.
   PubMed Web of Science ®Google Scholar
• Kucia M, Jankowski K, Reca R, et al. CXCR4-SDF-1 signaling, locomotion, chemotaxis and adhesion. J Mol Histol. 2003;35:233−245.
   Web of Science ®Google Scholar
• Moriuchi M, Moriuchi H, Turner W, et al. Cloning and analysis of the promoter region of CXCR4, a coreceptor for HIV-1 entry. J Immun. 1997;159:4322–4329.
   PubMed Web of Science ®Google Scholar
• Wright DE, Bowman EP, Wagers AJ, et al. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. J Exp Med. 2002;195:1145−1154.
   PubMed Web of Science ®Google Scholar
• Lee B, Sharron M, Montaner LJ, et al. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Nat Acd Sci. 1999;96:5215–5220.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Lysko PG, Pillarisetti K, et al. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J Biol Chem. 1998;273:4282–4287.
   PubMed Web of Science ®Google Scholar
• [cited 2019 August 29]. https://www.proteinatlas.org/ENSG00000107562-CXCL12/tissue
   Google Scholar
• Sanchez-Martin L, Estecha A, Smamaniego R, et al. The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood. 2011;117:88–97.
   PubMed Web of Science ®Google Scholar
• Boldajipour B, Mahabaleshwar H, Kardash E, et al. Control of chemokine-guided cell migration by ligand sequestration. Cell. 2008;132:463–473.
   PubMed Web of Science ®Google Scholar
• Ganju RK, Brubaker SA, Meyer J, et al. The alpha-chemokine, stromal cell-derived factor-1 alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem. 1998;273:23169–23175.
   PubMed Web of Science ®Google Scholar
• Tzeng Y, Li H, Kang YL, et al. Loss of CXCL12/SDF-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern on hematopoietic regeneration after myelosuppresion. Blood. 2011;117:429−439.
   PubMed Web of Science ®Google Scholar
• Zou Y, Kottman AH, Kuroda M, et al. The function of the chemokine receptor CXCR4 in hematopoiesis and in cellular development. Nature. 1998;393:595−599.
   PubMed Web of Science ®Google Scholar
• Mishan MA, Ahmadiankia N, Bahrami AR. CXCR4 and CCR7: two eligible targets in targeted cancer therapy. Cell Biol Int. 2016;40:955–967.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16:2927−2931.
   PubMed Web of Science ®Google Scholar
• Domanska UM, Kruizinga RC, Nagengstat WB, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Euro J Cancer. 2013;49:219–230.
   PubMed Web of Science ®Google Scholar
• Guo Q, Huang F, Goncalves C, et al. Translation of cancer immunotherapy from the bench to the bedside. Adv Cancer Res. 2019;143:1–62.
   PubMed Web of Science ®Google Scholar
• Domingues MJ, Nilsson SK, Cao B. New agents in HSC mobilization. Int J Hematol. 2017;105:141–152.
   PubMed Web of Science ®Google Scholar
• Choi W-T, Yang Y, Xu Y, et al. Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis. Curr Top Med Chem. 2014;14:1574–1589.
   PubMed Web of Science ®Google Scholar
• Li M, Hale JS, Rich JN, et al. Chemokine CXCL12 in neurodegenerative diseases: an SOS signal for stem cell-based repair. Trends Neurosci. 2012;35:619–628.
   PubMed Web of Science ®Google Scholar
• Tsou LK, Huang Y-H, Song J-S, et al. Harnessing CXCR4 antagonists in stem cell mobilization, HIV infection, ischemic diseases and oncology. Med Res Rev. 2018;38:1188–1234.
   PubMed Web of Science ®Google Scholar
• Mosley CA, Wilson LJ, Wiseman JM, et al. Recent patents regarding the discovery of small molecule CXCR4 antagonists. Expert Opin Ther Pat. 2009;19:23–38.
   PubMed Web of Science ®Google Scholar
• Choi W-T, Duggineni S, Xu Y, et al. Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4). J Med Chem. 2012;55:977–994.
   PubMed Web of Science ®Google Scholar
• Hendrix CW, Collier A, Lederman M, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acq Immune Def Synd. 2004;37:1253–1262.
   PubMed Web of Science ®Google Scholar
• De Clercq E. Mozobil (Plerixafor, AMD3100), 10 years after its approval by the food and drug administration. Antiviral Chem Chemother. 2019;27:1–8.
   Google Scholar
• Moyle G, DeJesus E, Boffito M, et al. Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1. Clin Infect Dis. 2009;48:798–805.
   PubMed Web of Science ®Google Scholar
• A dose determination and safety study of X4P-001 (Mavorixafor) in participants with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome. NCT03005327. [cited 2019 Aug 16] www.clinicltrials.gov.
   Google Scholar
• Andtbacka RHI, Pierce RH, Campbell JS et al. X4P-001, an orally bioavailable CXCR4 antagonist, enhances immune cell infiltration and activation in the tumor microenvironment of melanoma. Poster 613. AACR Annual Meeting, Chicago, IL, 2018 Apr 14–18.
   Google Scholar
• Jenkinson S, Thomson M, McCoy D, et al. Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist. Antimicrob Agents Chemother. 2010;54:817−824.
   PubMed Web of Science ®Google Scholar
• Murakami T, Kumakura S, Yamazaki T, et al. The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. Antimicrob Agents Chemother. 2009;53:2940–2948.
   PubMed Web of Science ®Google Scholar
• Pease J, Horuk R. Chemokine receptor antagonists. J Med Chem. 2012;55:9363–9392.
   PubMed Web of Science ®Google Scholar
• Wong RSY, Bodart V, Metz M, et al. Comparison of the potential multiple binding modes of bicyclam, monocyclam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharm. 2008;74:1485–1495.
   PubMed Web of Science ®Google Scholar
• Wu B, Chien EYT, Mol CD, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science. 2010;330:1066–1071.
   PubMed Web of Science ®Google Scholar
• Castaldo C, Benicchi T, Otrocka M, et al. CXCR4 antagonists: a screening strategy for identification of functionally selective ligands. J Biomol Screen. 2014;19:1–11.
   PubMedGoogle Scholar
• Van Hout A, D’huys T, Oeyen M, et al. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors. PLoS ONE. 2017;12:e0176057.
   PubMed Web of Science ®Google Scholar
• Peters MF, Scott CW. Evaluating cellular impedance assays for detection of gpcr pleiotropic signaling and functional selectivity. J Biomol Screen. 2009;14:246–255.
   PubMed Web of Science ®Google Scholar
• Lackman-Smith C, Osterling C, Luckenbaugh K, et al. Development of a comprehensive human immunodeficiency virus type I screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob Agents Chemother. 2008;52:1768−1781.
   PubMed Web of Science ®Google Scholar
• Huang M-B, Giesler KE, Katzman BM, et al. Small molecule CXCR4 antagonists block the HIV-1 Nef/CXCR4 axis and selectively initiate the apoptotic program in breast cancer cells. Oncotarget. 2018;9:16996–17013.
   PubMedGoogle Scholar
• Lack NA, Green B, Dale DC, et al. A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther. 2005;77:427−436.
   PubMed Web of Science ®Google Scholar
• Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med. 1962;111:544–547.
   PubMed Web of Science ®Google Scholar
• Emory University. CXCR4 antagonists for imaging of cancer and inflammatory disorders. US 20120294803A1. 2012.
   Google Scholar
• Emory University. Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction. US 9205085 2015.
   Google Scholar
• Liang Z, Zhan W, Zhu A, et al. Development of a unique small molecule modulator of CXCR4. PLoS One. 2012;7(4):e34038.
   PubMed Web of Science ®Google Scholar
• Safety/efficacy of Q-122 in breast cancer patients taking tamoxifen or aromatase inhibitor. NCT03518138. [cited 2019 Aug 5]. www.clincaltrials.gov
   Google Scholar
• Emory University. Bis-amines, compositions, and uses related to CXCR4 inhibition. WO2017011517A1 (2017).
   Google Scholar
• Gaines T, Camp D, Bai R, et al. Synthesis and evaluation of 2,5 and 2,6 pyridine-based CXCR4 inhibitors. Biorg Med Chem Lett. 2016;24:5052–5060.
   Google Scholar
• Ono Pharmaceuticals. Compound having spiro-bonded group and use thereof. US20120101280A1. 2012.
   Google Scholar
• Glycomimetics. Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors. WO2010126888A1. 2010.
   Google Scholar
• Glycomimetics. Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors. WO2016089872A1. 2016.
   Google Scholar
• Kureha Corporation. Amine compound and use for same. US2013/0245280A1. 2013.
   Google Scholar
• Nyunt M, Becker S, MacFarland RT, et al. Pharmacokinetic effect of AMD070, an oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromorphan in healthy volunteers. J Acquired Immune Defic Syndr. 2008;47:559−565.
   PubMed Web of Science ®Google Scholar
• Emory University. Chemokine CXCR4 receptor modulators and used related thereto. US 8,969,381 B2. 2015.
   Google Scholar
• Truax VM, Zhao H, Katzman BM, et al. Discovery of 1,2,3,4-tetrahydroisoquinoline based CXCR4 antagonists. ACS Medchem Lett. 2013;4:1025–1030.
   PubMed Web of Science ®Google Scholar
• Zhao H, Prosser AR, Liotta DC, et al. Discovery of novel piperazine CXCR4 antagonists. Bioorg Med Chem Lett. 2015;25:4950–4955.
   PubMed Web of Science ®Google Scholar
• Altiris Therapeutics. Chemokine receptor modulators. US 8,338,448 B2. 2013.
   Google Scholar
• Rettig MP, Ghobadi A, Holt M, et al. ALT-1188: A new CXCR4 antagonist in development for mobilization of HSPCs. Blood. 2013;122:891.
   Web of Science ®Google Scholar
• Bristol-Myers Squibb Company. CXCR4 receptor antagonists. WO 2017106291 A1. 2017.
   Google Scholar
• Emory University. Chemokine CXCR4 receptor modulators and uses related thereto. WO 2018156595 A1. 2018.
   Google Scholar
• Nguyen HH, Kim MB, Wilson RJ, et al. Design, synthesis, and pharmacological evaluation of second-generation tetrahydroisoquinoline-based CXCR4 antagonists with favorable ADME properties. J Med Chem. 2018;61:7168–7188.
   PubMed Web of Science ®Google Scholar
• X4 Pharmaceuticals Inc. CXCR4 inhibitors and uses thereof. WO 2017223229 A1. 2017.
   Google Scholar
• X4 Pharmaceuticals Inc. CXCR4 inhibitors and uses thereof. WO 2017223239 A1. 2017.
   Google Scholar
• X4 Pharmaceuticals Inc. CXCR4 inhibitors and uses thereof. WO 2017223243 A1. 2017.
   Google Scholar
• Emory University. Chemokine CXCR4 and CCR5 receptor modulators and uses related thereto. US 20170137401 A1. 2017.
   Google Scholar
• Cox B, Prosser AR, Sun Y, et al. Pyrazolo-piperidines exhibit dual inhibition of CCR5/CXCR4 HIV entry and reverse transcriptase. ACS Med Chem Lett. 2015;6:753–757.
   PubMed Web of Science ®Google Scholar
• Taigen Biotechnology Co. LTD. Pyrimidine compounds. US 8,193,206 B2. 2012.
   Google Scholar
• Taigen Biotechnology Co. LTD. Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor. US 9,375,406 B2. 2016.
   Google Scholar
• A study to evaluate the safety, pharmacokinetics, and hematopoietic stem cell mobilization of TG-0054 alone or in combination with G-CSF in patients with multiple myeloma, non-hodgkin lymphoma or hodgkin disease. NCT01458288. [cited 2019 Aug 16]. www.clinicaltrials.gov
   Google Scholar
• Proximagen Group Limited. CXCR4 receptor antagonists. WO 2012049277 A1. 2012.
   Google Scholar
• Proximagen Group Limited. Novel therapeutics for cancer. WO 2016157149 A1. 2016.
   Google Scholar
• Proximagen Group Limited. Combination of a CXCR4 antagonist and an immune checkpoint inhibitor. WO 2017153780 A1. 2017.
   Google Scholar
• Proximagen Group Limited. USL311 for use in the treatment of cancer. WO 2018162924 A1. 2018.
   Google Scholar
• Phase 1/2 study of USL311 alone and in combination with lomustine in subjects with advanced solid tumors and relapsed/recurrent glioblastoma multiforme (GBM). NCT02765165. [cited 2019 Aug 16]. www.clinicaltrials.gov
   Google Scholar
• University of Louisville Research Foundation, Inc. Compounds for treating disease, for administering, and for pharmaceutical compositions. US 8,785,490 B2. 2014.
   Google Scholar
• University of Louisville Research Foundation, Inc. Methods of treating CXCR4-expressing cancers. US 9,145,398 B2. 2015.
   Google Scholar
• Northwestern University. CXCR4 chemokine receptor modulators. WO 2016179349 A1. 2016.
   Google Scholar
• Allergan Inc. Aromatic bicyclic derivatives as CXCR4 modulators. WO 2013019966 A1. 2013.
   Google Scholar
• Schering Corporation, Albany molecular research institute. compounds useful as chemokine receptor antagonists. WO2011060394. 2011.
   Google Scholar
• Schering Corporation, Albany molecular research institute. substituted amino heterocycles useful as HIV antagonists. WO 2011060397. 2011.
   Google Scholar
• Labib M, Teintze M, Wilkinson RA. N-alkyl or N-aryl substituted guanide and biguanide compounds and methods of their use. WO2012047630 A2. 2012.
   Google Scholar
• Anchor Therapeutics. CXCR4 receptor compounds. WO2010053550A2. 2010.
   Google Scholar
• Anchor Therapeutics. CXCR4 receptor compounds. WO2011106703A2. 2011.
   Google Scholar
• Anchor Therapeutics. CXCR4 receptor compounds. US9155795B2. 2015.
   Google Scholar
• Tchernychev B, Ren Y, Sachdev P, et al. Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells. Proc Nat Acad Sci. 2010;107:22255–22259.
   PubMed Web of Science ®Google Scholar
• Pharis Biotech GMBH. CXC chemokine receptor 4 (CXCR4) antagonistic polypeptide. US9045563B2. 2015.
   Google Scholar
• Pharis Biotech GMBH. Peptides with antagonistic activities against natural CXCR4. WO2014198834A1. 2014.
   Google Scholar
• Curonz Holdings Co. Limited. Neural regeneration peptides and uses therefor. US20160031937A1. 2016.
   Google Scholar
• Dezsi G, Sieg F, Thomas M, et al. Disease-modifying effects of neural regeneration peptide 2945 in the GAERS model of absence epilepsy. Neurochem Res. 2017;42:2055–2064.
   PubMed Web of Science ®Google Scholar
• Phase I completed with 49 healthy volunteers in Australia. Phase II clincial study planned for refractory epilepsy in children diagnosed with Lennox-Gastaut Syndrome (LGS). [cited 2019 May]. http://www.curonz.com/index.htm
   Google Scholar
• Consiglio Nazionale Delle Ricerche. Cyclic peptides binding CXCR4 receptor and relative medical and diagnostic uses. WO2011092575A1. 2011.
   Google Scholar
• IRCCS-Stituto Nazionale Perlo Studio E La Curade Tumori. Cyclic peptides binding CXCR4 receptor and relative medical and diagnostic uses. US9102710B2. 2015.
   Google Scholar
• University of Southern California. Cyclotide-based CXCR4 antagonists with anti-HIV activity. WO2014046732A1. 2014.
   Google Scholar
• Mainline Biosciences. CXCR4 antagonists and methods of use. US20180066021A1. 2018.
   Google Scholar
• Polyphor AG. Beta-hairpin peptidomimetics having CXCR4 antagonizing activity. WO2010127704A1. 2010.
   Google Scholar
• Polyphor AG. Beta-hairpin peptidomimetics. US20120283196A1. 2012.
   Google Scholar
• Polyphor AG. Beta-hairpin peptidomimetics as CXCR4 antagonists. 2012. WO2012168336.
   Google Scholar
• Polyphor LTD. Template fixed peptidomimetics. US 8399611B2. 2013.
   Google Scholar
• Safety and efficacy of POL6326 for mobilization of hematopoietic stem cells in healthy volunteers. NCT01841476. [cited 2019 Aug 20]. www.clinicaltrials.gov
   Google Scholar
• Pivotal Study in HER2 Negative. Locally recurrent or metastatic breast cancer. NCT03786094. [cited 2019 Aug 20]. www.clinicaltrials.gov
   Google Scholar
• Polyphor AG Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity. WO2010060479A1. 2010.
   Google Scholar
• Polyphor AG Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity. US20110312879A1. 2011.
   Google Scholar
• Polyphor AG Beta-hairpin peptidomimetics. WO 2013182240 A1. 2013.
   Google Scholar
• Biokine Therapeutics. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma. US2013303460A1. 2013.
   Google Scholar
• Biokine Therapeutics. Methods of treating myeloid leukemia. WO2014155376A1. 2014.
   Google Scholar
• Eizenberg O, Peled A. The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation. Leukemia. 2009;23:1378–1388.
   PubMed Web of Science ®Google Scholar
• Tamamura H, Hori A, Kanzaki N, et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett. 2003;550:79–83.
   PubMed Web of Science ®Google Scholar
• Pembrolizumab and CXCR4 antagonist BL-8040 in treating patients with metastatic pancreatic cancer. NCT02907099. [cited 2019 Aug 20]. www.clinicaltrials.gov
   Google Scholar
• Barcelona University. Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells. EP2476441A1. 2012.
   Google Scholar
• Barcelona University. Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells. EP2663336B1. 2017.
   Google Scholar
• Corrales V, Gomez EV, Navarro MV, et al. Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells. US20140094404A1. 2014.
   Google Scholar
• Eli Lilly and Company. Cyclic peptide CXCR4 antagonists. US20100130409A1. 2010.
   Google Scholar
• LY2510924, idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia. NCT02652871. [cited 2019 Aug 20]. www.clinicaltrials.gov
   Google Scholar
• Addition of X4P-001 to nivolumab treatment in participants with renal cell carcinoma. NCT02923531. [cited 2019 Sep 6]. www.clinicaltrials.gov
   Google Scholar
• Kuhne MR, Mulvey T, Belanger B, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013;19:357–366.
   PubMed Web of Science ®Google Scholar
• First in human study to determine the safety, tolerability and preliminary efficacy of an anti-CXCR4 antibody in subjects with acute myelogenous leukemia and selected B-cell cancers. NCT01120457. [cited 2019 Sep 6]. www.clinicaltrials.gov
   Google Scholar
• A study of ulocuplumab and ibrutinib in symptomatic patients with mutated CXCR4 waldenstrom’s macroglobulinemia. NCT03225716. [cited 2019 Sep 6]. www.clinicaltrials.gov
   Google Scholar